Palmitoyl Tetrapeptide-7
Anti-inflammatory matrikine peptide that reduces IL-6-driven inflammaging for calmer, more youthful skin.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
3 % – 10 ppm
Compound profile
Scientific & efficacy data
Cosmetic
Peptide profile
Limited human trials
Palmitoyl Tetrapeptide-7
Under 10 ppm (<0.001%) in finished product · Once daily
Molecular formula
C34H62N8O7
- Mol. weight
- 694.9 Da
- CAS number
- 221227-05-0
- PubChem
- 10078408
- Developed · 2005
- Sederma research team
Sederma S.A. (part of Croda International)
Amino acid sequence
Pal-Gly-Gln-Pro-Arg (palmitoylated GQPR tetrapeptide)Anti-Inflammatory
Directly reduces IL-6 secretion in keratinocytes and fibroblasts, addressing the chronic inflammation that accelerates skin aging.
Anti-Aging
Modulates inflammaging pathways and senescence-associated secretory phenotype to slow age-related skin deterioration at the cellular level.
Skin Barrier Support
Stimulates laminin and nidogen production at the dermal-epidermal junction, strengthening structural integrity and barrier resilience.
Dosing
How much do I take?
3 % – 10 ppm
3 % – 10 ppm
Covers all 2 documented dose levels · timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for individuals with aging skin showing signs of chronic low-grade inflammation & those seeking to reduce uv-damage-related skin aging (photoaging)
Best for
Individuals with aging skin showing signs of chronic low-grade inflammation
Palmitoyl Tetrapeptide-7 is particularly well-suited for individuals focused on individuals with aging skin showing signs of chronic low-grade inflammation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Those seeking to reduce UV-damage-related skin aging (photoaging)
Palmitoyl Tetrapeptide-7 is particularly well-suited for individuals focused on those seeking to reduce uv-damage-related skin aging (photoaging). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
People looking for synergistic peptide therapy in Matrixyl 3000 products
Palmitoyl Tetrapeptide-7 is particularly well-suited for individuals focused on people looking for synergistic peptide therapy in matrixyl 3000 products. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Individuals with sensitive or reactive skin benefiting from anti-inflammatory peptides
Palmitoyl Tetrapeptide-7 is particularly well-suited for individuals focused on individuals with sensitive or reactive skin benefiting from anti-inflammatory peptides. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Palmitoyl Tetrapeptide-7 with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Topical
Route
Palmitoyl Tetrapeptide-7 is administered Topical—no injection required
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
4 common side effects · 2 serious
Palmitoyl tetrapeptide-7 (Eyeliss) shows excellent safety for periocular use with minimal irritation potential (Draize score <0.5 at 2% concentration).
No serious adverse events in cosmetic formulations used for 15+ years. Eye irritation testing per OECD 404 confirms safety; no systemic toxicity in repeat-dose oral studies. Mild local effects limited to topical application site with no dermal penetration.
Clinical efficacy measured through non-invasive imaging (ultrasound, photography analysis) demonstrates edema reduction in periocular area with 25-40% visible improvement in eye puffiness after 4 weeks application.
Lymphatic circulation enhancement quantified through fluorescence microlymphography studies. Safety dermatology panel testing confirms ISO 10993 biocompatibility with no irritation at concentrations up to 3%.
Common side effects · experienced by some users
Mild Redness
Temporary mild redness at application site in sensitive individuals. Generally self-resolving within 15-30 minutes.
Management: Perform patch test before first use. If persistent, reduce application frequency.
Slight Tingling
Brief tingling sensation upon application, particularly on skin with compromised barrier.
Management: Normal response for active peptides. Should subside quickly. Ensure skin barrier is intact.
Mild Irritation with Other Actives
Potential for additive mild irritation when layered with multiple active ingredients simultaneously.
Management: Simplify skincare routine. Apply peptide products separately from retinoids or strong acids.
Dryness
Occasional dryness when combined with drying formulations or in very arid environments.
Management: Follow peptide serum with a hydrating moisturizer to seal in benefits.
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Palmitoyl Tetrapeptide-7
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Palmitoyl Tetrapeptide-7 should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:Palmitoyl Tripeptide-1 — May be used together under medical guidance.
- Safe:Hyaluronic Acid — May be used together under medical guidance.
- Safe:Niacinamide — May be used together under medical guidance.
With medications
- Caution:Strong Chemical Peels — Use with caution—discuss with your healthcare provider.
- Caution:High-Concentration Retinoids (initially) — Use with caution—discuss with your healthcare provider.
- Caution:Strong Oxidizing Agents — Use with caution—discuss with your healthcare provider.
With supplements
- Safe:Multivitamins — Generally safe to take alongside Palmitoyl Tetrapeptide-7. Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Limited human trials · first signs weeks 1-4
Evidence level
Limited human trials
Regulatory status
Research compound
Onset of effects
Moderate
(1-2 weeks)
How it works
Palmitoyl-tetrapeptide-7 (Matrixyl 3000) is a lipidated signal peptide that both stimulates collagen production AND reduces inflammation in skin.
By combining collagen-building with anti-inflammatory effects, it addresses multiple aging mechanisms at once, improving skin texture, firmness, and reducing redness or irritation.
The deeper mechanism
Palmitoyl-tetrapeptide-7 (Matrixyl 3000) is a four-amino acid peptide conjugated to palmitic acid that combines signal peptide-mediated fibroblast activation with anti-inflammatory effects.
The lipid moiety enhances skin penetration and bioavailability, while the tetrapeptide sequence activates TGF-β-responsive fibroblasts to increase type I and III collagen synthesis and dermal matrix deposition.
Additionally, palmitoyl-tetrapeptide-7 inhibits pro-inflammatory cytokine production (TNF-α, IL-6) and suppresses NF-κB activation in dermal cells, reducing chronic inflammation associated with photoaging.
The dual collagen-stimulating and anti-inflammatory mechanism addresses both structural aging (collagen loss) and inflammatory aging (oxidative stress and cytokine-driven matrix degradation), producing more comprehensive anti-aging benefits than single-mechanism peptides.
What to expect
Weeks 1-4
What you might notice
- Anti-inflammatory signaling begins reducing IL-6 levels in skin
- Early improvements in skin calmness and reduced reactivity
- Skin texture may feel smoother and more even
What's normal
- Full integration of Palmitoyl Tetrapeptide-7 into physiological systems is established
- Long-term Palmitoyl Tetrapeptide-7 response remains personalized to your physiology
- Palmitoyl Tetrapeptide-7 tolerance is well-maintained with consistent dosing
What's next
- Maintain your established Palmitoyl Tetrapeptide-7 protocol for sustained benefits
- Continue periodic monitoring to confirm Palmitoyl Tetrapeptide-7 efficacy
- Review comprehensive Palmitoyl Tetrapeptide-7 response with your provider
Weeks 4-12
What you might notice
- Sustained reduction in inflammaging markers
- Improvements in skin tone and reduced redness from chronic inflammation
- Laminin and nidogen production enhance dermal-epidermal junction integrity
What's normal
- Palmitoyl Tetrapeptide-7 is now achieving steady-state pharmacokinetics
- Measurable changes aligned with Palmitoyl Tetrapeptide-7's mechanism may appear
- Initial adjustment effects typically resolve by this point
What's next
- Maintain Palmitoyl Tetrapeptide-7 dosing exactly as established
- Track progress toward intended outcomes in detail
- Review lab work or biomarker changes with your healthcare team
Weeks 12-24+
What you might notice
- Cumulative anti-inflammatory benefits produce visible improvements in skin firmness and resilience
- When combined with Palmitoyl Tripeptide-1, comprehensive anti-aging results including wrinkle reduction and improved elasticity
What's normal
- Full therapeutic effects of Palmitoyl Tetrapeptide-7 are well-characterized at this point
- Maintenance of Palmitoyl Tetrapeptide-7's therapeutic effects is typical
- Tolerance patterns with Palmitoyl Tetrapeptide-7 are generally stable over months
What's next
- Comprehensive assessment of Palmitoyl Tetrapeptide-7 efficacy should be conducted
- Discuss long-term continuation, cycling, or protocol modifications
- Continue regular monitoring of relevant biomarkers or symptoms
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Palmitoyl Tetrapeptide-7 over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Questions
Frequently asked
What is inflammaging and how does Palmitoyl Tetrapeptide-7 address it?
Inflammaging is chronic low-grade inflammation that increases with age, driven partly by senescent cells releasing pro-inflammatory cytokines like IL-6. This persistent inflammation degrades collagen, breaks down the extracellular matrix, and accelerates skin aging. Palmitoyl Tetrapeptide-7 directly reduces IL-6 secretion, helping to quiet this inflammatory cycle and protect the skin matrix from inflammation-driven degradation.
Can Palmitoyl Tetrapeptide-7 be used alone or only in Matrixyl 3000?
While most effective as part of Matrixyl 3000 with Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7 can be used independently for its anti-inflammatory benefits. It is particularly useful in formulations targeting sensitive, reactive, or inflammation-prone skin. However, for comprehensive anti-aging results including collagen building, the synergistic combination in Matrixyl 3000 is recommended.
How does this differ from other anti-inflammatory skincare ingredients?
Unlike broad anti-inflammatory botanicals (like centella or green tea), Palmitoyl Tetrapeptide-7 specifically targets IL-6 cytokine signaling in skin cells, providing a more targeted approach to inflammaging. It also stimulates structural proteins (laminin, nidogen) at the dermal-epidermal junction, offering both anti-inflammatory and structural repair benefits that botanical anti-inflammatories do not provide.
Is Palmitoyl Tetrapeptide-7 the same as Palmitoyl Tetrapeptide-3?
Yes. Palmitoyl Tetrapeptide-7 was formerly known as Palmitoyl Tetrapeptide-3 (and marketed as Rigin). The name was updated to Palmitoyl Tetrapeptide-7 under INCI nomenclature revisions, but the molecule and its properties are identical.
Does Palmitoyl Tetrapeptide-7 help with sun damage?
Yes. Research shows it reduces IL-6 secretion specifically in UVB-stressed keratinocytes, meaning it helps mitigate the inflammatory response triggered by UV exposure. While not a sunscreen replacement, it can help reduce the inflammation-driven damage that accelerates photoaging when used as part of a post-sun or daily anti-aging regimen.
Further reading
History & related research
History · since 2003
The skin calmer that stops inflammation before it starts
Palmitoyl Tetrapeptide-7 is a short peptide made from four amino acids. Scientists attached a fatty acid chain to help it sink into skin.
Read the full history of Palmitoyl Tetrapeptide-7Ready for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Palmitoyl Tetrapeptide-7, on one page.